LEADER 04714nam 22007935 450 001 9910522990003321 005 20250604132413.0 010 $a9783030825874$b(electronic bk.) 010 $z9783030825867 024 7 $a10.1007/978-3-030-82587-4 035 $a(MiAaPQ)EBC6824266 035 $a(Au-PeEL)EBL6824266 035 $a(CKB)20094234600041 035 $a(DE-He213)978-3-030-82587-4 035 $a(EXLCZ)9920094234600041 100 $a20211209d2022 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEvidence-biased Antidepressant Prescription $eOvermedicalisation, Flawed Research, and Conflicts of Interest /$fby Michael P. Hengartner 205 $a1st ed. 2022. 210 1$aCham :$cSpringer International Publishing :$cImprint: Palgrave Macmillan,$d2022. 215 $a1 online resource (355 pages) 311 08$aPrint version: Hengartner, Michael P. Evidence-Biased Antidepressant Prescription Cham : Springer International Publishing AG,c2022 9783030825867 320 $aIncludes bibliographical references and index. 327 $a1. Introduction: How did I get here? -- 2. Antidepressants in clinical practice -- 3. Medico-cultural context -- 4. Flaws in antidepressant research -- 5. Conflicts of interest in psychiatry -- 6. Solutions for reform. 330 $aThis book addresses the over-prescribing of antidepressants in people with mostly mild and subthreshold depression. It outlines the steep increase in antidepressant prescription and critically examines the current scientific evidence on the efficacy and safety of antidepressants in depression. The book is not only concerned with the conflicting views as to whether antidepressants are useful or ineffective in various forms of depression, but also aims at detailing how flaws in the conduct and reporting of antidepressant trials have led to an overestimation of benefits and underestimation of harms. The transformation of the diagnostic concept of depression from a rare but serious disorder to an over-inclusive, highly prevalent but predominantly mild and self-limiting disorder is central to the books argument. It maintains that biological reductionism in psychiatry and pharmaceutical marketing reframed depression as a brain disorder, corroborating the overemphasis on drug treatment in both research and practice. Finally, the author goes on to explore how pharmaceutical companies have distorted the scientific literature on the efficacy and safety of antidepressants and how patient advocacy groups, leading academics, and medical organisations with pervasive financial ties to the industry helped to promote systematically biased benefit-harm evaluations, affecting public attitudes towards antidepressants as well as medical education, training, and practice. Michael P. Hengartner is a senior researcher and lecturer at the Zurich University of Applied Sciences, Switzerland. He has published over 130 peer-reviewed journal articles and four book chapters. He was an expert evaluator for the European Research Council and the World Health Organization and currently is a member of the Swiss School of Public Health, the German Society for Social Psychiatry,and the European Public Health Association. 606 $aClinical psychology 606 $aPsychiatry 606 $aSocial medicine 606 $aMedical anthropology 606 $aPsychology, Pathological 606 $aPublic health 606 $aClinical Psychology 606 $aPsychiatry 606 $aMedical Sociology 606 $aMedical Anthropology 606 $aPsychopathology 606 $aPublic Health 606 $aAntidepressius$2thub 606 $aPrescripció de medicaments$2thub 606 $aMedicina basada en l'evidčncia$2thub 608 $aLlibres electrňnics$2thub 615 0$aClinical psychology. 615 0$aPsychiatry. 615 0$aSocial medicine. 615 0$aMedical anthropology. 615 0$aPsychology, Pathological. 615 0$aPublic health. 615 14$aClinical Psychology. 615 24$aPsychiatry. 615 24$aMedical Sociology. 615 24$aMedical Anthropology. 615 24$aPsychopathology. 615 24$aPublic Health. 615 7$aAntidepressius 615 7$aPrescripció de medicaments 615 7$aMedicina basada en l'evidčncia 676 $a615.78 676 $a616.8527061 700 $aHengartner$b Michael P.$01079894 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910522990003321 996 $aEvidence-Biased Antidepressant Prescription$92592625 997 $aUNINA